Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Celcuity Inc. (CELC) announced that REVTORPYK (gedatolisib) is now commercially available in the U.S. for HR+/HER2- advanced breast cancer patients without a PIK3CA mutation. The FDA approved REVTORPYK in July 2026 for use in combination with palbociclib and fulvestrant, or fulvestrant alone. The company also launched a support program for patient access and financial assistance.
How this was made
The 30-second read
Why it matters
The commercial launch translates regulatory approval into revenue potential, a key catalyst for a small‑cap biotech.
Market read
First‑time availability of a novel oncology drug creates a fresh trading catalyst for CELC.
What to watch
Potential competition from other PI3K/mTOR agents and the need for payer coverage may limit uptake.
Background
Celcuity is a Nasdaq‑listed biotech focused on targeted therapies for solid tumors.
Ticker impact
Celcuity Inc. announced that its FDA‑approved therapy REVTORPYK (gedatolisib) is now commercially available in the United States.
likely upside as the market prices in the product launch and potential sales growth
First‑time commercial availability of a novel PI3K/mTOR inhibitor creates immediate commercial upside, though execution risk remains.
Market effects
Adds a new competitor in the HR+/HER2‑negative breast‑cancer space, may pressure other PI3K inhibitors.
U.S. biotech sector could see modest uplift from the launch.
Limited to U.S. market; global impact modest.
Counterpoint
If reimbursement is slow or safety concerns arise, the launch could disappoint and pressure the stock.
Key entities
- companyCelcuity Inc.
Biotech developer of REVTORPYK.
- productREVTORPYK (gedatolisib)
First FDA‑approved pan‑PI3K/mTOR inhibitor for HR+/HER2‑negative advanced breast cancer.
